MX2024011654A - Formulaciones que comprenden melfalan flufenamida y ciclodextrina - Google Patents
Formulaciones que comprenden melfalan flufenamida y ciclodextrinaInfo
- Publication number
- MX2024011654A MX2024011654A MX2024011654A MX2024011654A MX2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclodextrin
- flufenamide
- formulations including
- including melphalan
- melphalan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2204171.9A GB202204171D0 (en) | 2022-03-24 | 2022-03-24 | Novel formulations |
| PCT/EP2023/057729 WO2023180565A1 (en) | 2022-03-24 | 2023-03-24 | Formulations comprising melphalan flufenamide and cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011654A true MX2024011654A (es) | 2025-01-09 |
Family
ID=81449463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011654A MX2024011654A (es) | 2022-03-24 | 2024-09-23 | Formulaciones que comprenden melfalan flufenamida y ciclodextrina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250205155A1 (https=) |
| EP (1) | EP4499049A1 (https=) |
| JP (1) | JP2025510725A (https=) |
| KR (1) | KR20240161664A (https=) |
| CN (1) | CN119053323A (https=) |
| AU (1) | AU2023241241A1 (https=) |
| CA (1) | CA3245985A1 (https=) |
| GB (1) | GB202204171D0 (https=) |
| IL (1) | IL315551A (https=) |
| MX (1) | MX2024011654A (https=) |
| WO (1) | WO2023180565A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025233915A1 (en) * | 2024-05-10 | 2025-11-13 | Allgenesis Biotherapeutics Inc. | Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| DK2701720T3 (en) | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| SMT202000058T1 (it) | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| US12152087B2 (en) | 2018-10-18 | 2024-11-26 | Oncopeptides Innovation Ab | Deuterated melflufen compounds |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
-
2022
- 2022-03-24 GB GBGB2204171.9A patent/GB202204171D0/en not_active Ceased
-
2023
- 2023-03-24 WO PCT/EP2023/057729 patent/WO2023180565A1/en not_active Ceased
- 2023-03-24 JP JP2024556113A patent/JP2025510725A/ja active Pending
- 2023-03-24 IL IL315551A patent/IL315551A/en unknown
- 2023-03-24 CN CN202380035203.1A patent/CN119053323A/zh active Pending
- 2023-03-24 CA CA3245985A patent/CA3245985A1/en active Pending
- 2023-03-24 US US18/849,977 patent/US20250205155A1/en active Pending
- 2023-03-24 EP EP23720032.4A patent/EP4499049A1/en active Pending
- 2023-03-24 KR KR1020247034012A patent/KR20240161664A/ko active Pending
- 2023-03-24 AU AU2023241241A patent/AU2023241241A1/en active Pending
-
2024
- 2024-09-23 MX MX2024011654A patent/MX2024011654A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023241241A1 (en) | 2024-10-31 |
| CA3245985A1 (en) | 2023-09-28 |
| WO2023180565A1 (en) | 2023-09-28 |
| EP4499049A1 (en) | 2025-02-05 |
| US20250205155A1 (en) | 2025-06-26 |
| CN119053323A (zh) | 2024-11-29 |
| JP2025510725A (ja) | 2025-04-15 |
| KR20240161664A (ko) | 2024-11-12 |
| GB202204171D0 (en) | 2022-05-11 |
| IL315551A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| BR112022007867A2 (pt) | Degradadores de pequena molécula de helios e métodos de uso | |
| BR112021021857A2 (pt) | Métodos para formação de complexos de inclusão com derivados de beta-ciclodextrina hidrofílicos e composições dos mesmos | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| MX392213B (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| MX2021006969A (es) | Ligante peptidico. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| AR117652A1 (es) | Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas | |
| BR112023015272A2 (pt) | Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| WO2022106902A3 (en) | Benzenesulfonamide derivatives and uses thereof | |
| PE20250835A1 (es) | Composiciones y uso de la tirzepatida | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| MX2024011654A (es) | Formulaciones que comprenden melfalan flufenamida y ciclodextrina | |
| WO2023064612A3 (en) | Pharmaceutical compositions for delivery of viral antigens and related methods | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| CL2024001073A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| PH12022551810A1 (en) | Protein-antiviral compound conjugates | |
| MX2025013861A (es) | Compuestos anti virus de la inmunodeficiencia humana (vih) | |
| PH12021551396A1 (en) | Active ester derivatives of testosterone, compositions and uses thereof |